Compare Enveric Biosciences Inc (ENVB) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kinross Gold Corporation — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Kinross Gold Corporation trades at $22.88 (market cap $27.94B). The key difference: Kinross Gold Corporation is far larger — about 5251.9× Enveric Biosciences Inc's market cap, and Kinross Gold Corporation pays a 0.61% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | KGC | |
|---|---|---|
Market Cap | $5.32M | $27.94B |
Sector | Health | Basic Materials |
52-Week High | $17.40 | $38.06 |
52-Week Low | $1.28 | $15.33 |
Enterprise Value | $408.82K | $26.49B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Kinross Gold (KGC) trades at $23.91, up 1.83% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals, with Q1 2026 EPS of $0.71 beating expectations and robust profitability margins. Revenue grew to $7.05 billion in 2025, with net income reaching $2.39 billion. Recent news highlights exploration updates and Q2 2026 results due July 29, 2026.
KGC presents a compelling value with a P/E of 10.07 and consensus price target of $37.20, implying significant upside. Strengths include strong cash flow growth and a healthy balance sheet. Risks involve potential margin pressure from rising costs and gold price volatility. Analyst sentiment is bullish with 59% buy ratings, supporting a positive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
